북미 레버 선천성 아마우로시스 시장 – 2029년까지의 산업 동향 및 예측

Market Analysis and Insights

North America leber congenital amaurosis market is driven by the factors such as an increase in the prevalence of chronic diseases such as diabetes & gastrointestinal disorders, a growing number of the up-coming players and the popularity of infusion pumps in-home care services, which enhance its demand, as well as increasing investment in research and development, leads to the market growth. Currently, various research studies are taking place, which is expected to create a competitive advantage for manufacturers to develop new and innovative leber congenital amaurosis treatments and therapies, which is expected to provide various other opportunities in the leber congenital amaurosis market. However, the strict government regulations on approval and device errors during infusion therapy are expected to hamper the growth.

North America leber leber congenital amaurosis market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal to rising preference among customers due to guaranteed payment and high international sales of the product are the major drivers which propelled the demand of the market in the forecast period.

North America leber congenital amaurosis market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that North America leber congenital amaurosis market will grow at a CAGR of 4.4% during the forecast period of 2022 to 2029.

North America Leber Congenital Amaurosis Market Dynamics

Drivers

• Increase in pipeline products and clinical trials

The continuous innovation for the treatment of inherited retinal diseases and leber congenital amaurosis disorder has the potential to positively impact the market as the size of the market will increase, when these products will have approved in the North America market. Due to no pharmacological treatments for the LCA the major market players are continuously innovating the treatment or investing in the R&D for the treatment. Various ongoing clinical trials are recruiting worldwide to find the mechanism of diseases for treatment.

• Increase in strategic initiative by key players

Strategic initiatives such as collaboration, agreement, and signing of sales agreements to invent and innovate pharmacological treatments are expected to drive the market. Association, the deal is used by the primary player to the market expansion to a different region of the world along with the passing of technology from one player to others which increases product approval and institutional research.

Increasing partnership agreements and collaboration to increase the presence of companies in the eye disorder market will act as drivers for the market. The market player has gone through various strategic initiatives that will drive the growth of the  leber congenital amaurosis market.

• Increase in incidence and prevalence of rpe65 gene-mediated in retinal diseases

Inherited retinal dystrophies (IRDs) represent a genetically diverse group of progressive, visually debilitating diseases. Adult and pediatric patients with vision loss due to IRD caused by biallelic mutations in the 65-kDa retinal pigment epithelium (RPE65) gene are often clinically diagnosed as retinitis pigmentosa (RP), and Leber congenital amaurosis (LCA).

Leber congenital amaurosis (LCA) is an eye disorder that primarily affects the retina. LCA is characterized by severe visual impairment from birth or the first few months of life, roving eye movements or nystagmus, poor pupillary light responses, oculo digital sign (poking, rubbing, and/or pressing of the eyes), and undetectable or severely abnormal full-field electroretinogram (ERG). LCA is usually inherited as an autosomal recessive genetic condition.

Opportunities

•  Increase in government initiatives toward leber congenital amaurosis

According to WHO, the prevalence of monogenic IRDs is it affects about 1 in 40,000 new-borns North America. To prevent these, the government of several countries across the globe have taken initiatives.

The various programs and decisions taken by the government around the world for giving the best treatment to their population is the major factor that is expected to increase the demand and will act as an opportunity for the North America leber congenital amaurosis market.

Restraints/Challenges

• High cost associated with procedure and treatment

The cost of the product plays a major factor in the market. In the inherited retinal diseases market, it is generally observed that the cost of the products is highly sophisticated, need to be precise, and other specifications increase the product's cost. The high cost of the treatment is due to the various checkpoints of the treatment along with the use of high-tech modalities to perform such treatment procedures.

The cost of the product plays a major factor in the market. In the inherited retinal diseases market, it is generally observed that the cost of the products is highly sophisticated, need to be precise, and other specifications increase the product's cost. Moreover, the cost associated with treatment for a longer duration is quite difficult for an average-income person to afford. Utilizations of critical care and intensive care unit services are increasing worldwide, along with their expensive cost is a major concern in the current healthcare system.

Patients with a genetic disorder are commonly required to have long treatment with frequent monetarization and other usage leading to consuming a significant amount of healthcare resources. Due to this, most patients who cannot afford long-term economic costs get discharged in the initial stages of treatment.  But this increases the possibilities and susceptibilities for new complications in the diagnosis which demands additional healthcare resources and treatment.

The high cost of the treatment is due to the various checkpoints of the treatment along with the use of high-tech modalities to perform such treatment procedures.

The hospital care further adds to the cost of the leber congenital amaurosis. As the cost of innovative and advanced products is high, the cost of the treatment proportionally gets escalated, due to which high cost associated with Leber congenital amaurosis treatment and diagnosis is expected to restrain the   leber congenital amaurosis market growth.

Recent Developments

• In April 2021, Invitae Corporation opened a new laboratory and production facility in North Carolina to further expand its capacity to meet the growing demand for genetic testing services  ly
• In July 2017, Spark Therapeutics, Inc submitted the Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for LUXTURNA, the proposed trade name for voretigene neparvovec. This has increased company’s revenue and product portfolio.

North America Leber Congenital Amaurosis Market Divide

North America leber congenital amaurosis market is categorized into disease type, type, end-user, and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Disease Type

• Infantile Type
• Juvenile Type
• Others

On the basis of disease type, the leber congenital amaurosis market is segmented into infantile type, juvenile type & others

Type

• Diagnosis
• Therapy

On the basis by type, the leber congenital amaurosis market is segmented into diagnosis and therapy. Diagnosis segment is further segmented into clinical diagnosis and genetic diagnosis. Clinical diagnosis is further segmented into clinical eye examination, visual field test, retail imaging, and electro physiological tests. Clinical diagnosis is sub-segmented into electrophysiological tests, retinal imaging, visual field test and clinical eye examination. Electrophysiology tests is subsegmented into full-field electroretinogram (ERG) and dark adaptometry (DA). Retinal imaging is subsegmented into optical coherence tomography (OCT), fundus autofluorescence imaging (FAF), scanning laser ophthalmoscopy (SLO) and adaptive optics (AO) imaging and conventional color fundus imaging. Visual field tests is sub-segmented into computerized visual field tests and manual field test. Clinical examination is sub-segmented into slit lamp, indirect ophthalmoscopy, refraction test and dilation exam. Therapy segment is further segmented into gene therapy, retinal therapy, neuroprotective agents, and others. Gene therapy is further segmented into luxturna and others. Neuroprotective agents are further segmented into vitamin A palmitate, docosahexaenoic acid (DHA), lutein, and others.

End User

• Hospitals
• Specialty clinics
• Ambulatory surgical centers
• Home healthcare
• Others

On the basis of end user, the leber congenital amaurosis market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare, and others.

Distribution Channel

• Retail Sales
• Direct Tender

On the basis of distribution channel, the leber congenital amaurosis market is segmented into retail sales, direct tender.

Leber Congenital Amaurosis Market Regional Analysis/Insights

The leber congenital amaurosis market is analyzed and market size insights and trends are provided by country, disease type, type, end user, and distribution channel as referenced above.

The countries covered in the leber congenital amaurosis market report are U.S., Canada, and Mexico.

The U.S. is expected to dominate due to increasing pipeline products and clinical trials.

보고서의 국가 섹션은 또한 현재 및 미래 시장 추세에 영향을 미치는 개별 시장 영향 요인과 시장 규제의 변화를 제공합니다. 다운스트림 및 업스트림 가치 사슬 분석, 기술 추세 및 포터의 5가지 힘 분석, 사례 연구와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 몇 가지 포인터입니다. 또한 글로벌 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 국내 관세 및 무역 경로의 영향은 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.   

경쟁 환경 및 점유율 분석

북미 레버 선천성 아마우로시스 시장 경쟁 구도는 경쟁자에 대한 세부 정보를 제공합니다. 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 북미 지역 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 응용 분야 우세 등이 포함됩니다. 위에 제공된 데이터 포인트는 레버 선천성 아마우로시스 시장에 대한 회사의 초점과만 관련이 있습니다.

주요 기업으로는 Invitae Corporation, Johnson & Johnson Services, Inc., Spark Therapeutics, Inc., LKC TECHNOLOGIES, INC., Amarantus Bioscience Holdings, Inc., Sucampo Pharmaceuticals, Inc., Orphagen Pharmaceuticals, Inc. 등이 있습니다.

연구 방법론

데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석 및 추정됩니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 기본(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 이 외에도 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 회사 시장 점유율 분석, 측정 표준, 북미 대 지역 및 공급업체 점유율 분석이 포함됩니다. 추가 문의 사항이 있는 경우 분석가 전화를 요청하십시오.

SKU-68124